Evidence map›Paper›PMID 40427499›Full record

ArticleBiomolecules2025

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering.

Olga Bednova, Jessica Pougoue Ketchemen, Hazem Mslati, Mark Barok, Heikki Joensuu, Natalie Zeytuni, Francesco Gentile, Leon Sanche, Humphrey Fonge, Jeffrey Victor Leyton

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olga BednovaDépartement de Médecine Nucléaire et Radiobiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-6737-1784
Jessica Pougoue KetchemenFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-4574-8720
Hazem MslatiDepartment of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Mark BarokHelsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-9585-7669
Heikki JoensuuHelsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0003-0281-2507
Natalie ZeytuniDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.ORCID 0000-0002-5708-4095
Francesco GentileDepartment of Chemistry and Biomedical Sciences, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Leon SancheDépartement de Médecine Nucléaire et Radiobiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0003-0938-439X
Humphrey FongeFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.
Jeffrey Victor LeytonDepartment of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0001-6870-3819

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based agents have become a preferred treatment for various diseases, including cancer, due to significant advances in antibody engineering. The use of single-chain Fv-Fcs (scFv-Fcs) has been a promising engineering approach for therapeutic design. The concept is that the Fc provides increased stability and target binding and ultimately improves performance. However, the structural and dynamic relationship between the variable and Fc domains, which are fused in close proximity, and the impact on stability and target binding are not well understood. This study evaluated trastuzumab-derived scFv-Fc antibodies, focusing on the impact of their design on important biopharmaceutical parameters. Computational modelling and molecular dynamics, alongside experimental studies, were used to ascertain their dynamics, expression and purification, stabilities, and binding potencies. The results showed that the scFv subunits exhibited stochastic interplays that lead to diverse shapes and were associated with functional performance. This new understanding of scFv-Fc antibodies and their structural and functional nuances provides important details to further guide the design of more effective and less toxic therapeutics.

Indexed as

Immunoglobulin Fc FragmentsProtein EngineeringSingle-Chain AntibodiesTrastuzumabHumansMolecular Dynamics SimulationImmunoglobulin Fc FragmentsSingle-Chain AntibodiesTrastuzumabantibody engineeringHER2molecular dynamic simulationscFv-Fctrastuzumab

Identifiers

PMID40427499
PMCPMC12108635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.